Stan Deresinski

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Immunotherapies for Staphylococcus aureus: current challenges and future prospects
    Stan Deresinski
    Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA
    Infect Control Hosp Epidemiol 31:S45-7. 2010
  2. doi request reprint Antibiotic therapy of vascular catheter-related bloodstream infections: is vancomycin the optimal choice for Staphylococcus aureus infections?
    Stan Deresinski
    Department of Medicine, Division of Infectious Disease and Geographic Medicine, Stanford University, 2900 Whipple Ave, Ste 115, Redwood City, CA 94062, USA
    Int J Antimicrob Agents 34:S43-6. 2009
  3. doi request reprint Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections
    Stan Deresinski
    Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, CA, USA
    Clin Infect Dis 49:1072-9. 2009
  4. ncbi request reprint Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey
    Stan Deresinski
    Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA, USA
    Clin Infect Dis 40:562-73. 2005
  5. ncbi request reprint Vancomycin: does it still have a role as an antistaphylococcal agent?
    Stan Deresinski
    Division of Infectious Disease and Geographic Medicine, Stanford University, Stanford, CA, USA
    Expert Rev Anti Infect Ther 5:393-401. 2007
  6. ncbi request reprint Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence
    Stan Deresinski
    Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, CA, USA
    Clin Infect Dis 44:1543-8. 2007
  7. ncbi request reprint Antistaphylococcal vaccines and immunoglobulins: current status and future prospects
    Stan Deresinski
    Stanford University, Stanford, California, USA
    Drugs 66:1797-806. 2006
  8. ncbi request reprint Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data
    Stan Deresinski
    Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA, USA
    Clin Infect Dis 45:S177-83. 2007
  9. doi request reprint Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent
    Vijayalakshmi Nagappan
    Division of Infectious Diseases, St John Hospital and Medical Center, Detroit, Michigan, USA
    Clin Infect Dis 45:1610-7. 2007

Collaborators

  • Vijayalakshmi Nagappan

Detail Information

Publications10

  1. doi request reprint Immunotherapies for Staphylococcus aureus: current challenges and future prospects
    Stan Deresinski
    Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA
    Infect Control Hosp Epidemiol 31:S45-7. 2010
    ..We present a brief overview of the current knowledge in this field, with emphasis on present challenges and lessons learned, together with a summary of vaccines and immunoglobulin preparations currently under investigation...
  2. doi request reprint Antibiotic therapy of vascular catheter-related bloodstream infections: is vancomycin the optimal choice for Staphylococcus aureus infections?
    Stan Deresinski
    Department of Medicine, Division of Infectious Disease and Geographic Medicine, Stanford University, 2900 Whipple Ave, Ste 115, Redwood City, CA 94062, USA
    Int J Antimicrob Agents 34:S43-6. 2009
    ..The relative efficacy of alternative therapies requires urgent investigation in randomized clinical trials...
  3. doi request reprint Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections
    Stan Deresinski
    Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, CA, USA
    Clin Infect Dis 49:1072-9. 2009
    ..Clinicians should carefully reconsider the use of vancomycin-based combination therapies for the treatment of infection due to methicillin-resistant S. aureus...
  4. ncbi request reprint Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey
    Stan Deresinski
    Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA, USA
    Clin Infect Dis 40:562-73. 2005
    ..This has led to an important change in the choice of antibiotics in the management of community-acquired infections and has also led to the development of novel antimicrobials...
  5. ncbi request reprint Vancomycin: does it still have a role as an antistaphylococcal agent?
    Stan Deresinski
    Division of Infectious Disease and Geographic Medicine, Stanford University, Stanford, CA, USA
    Expert Rev Anti Infect Ther 5:393-401. 2007
    ....
  6. ncbi request reprint Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence
    Stan Deresinski
    Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, CA, USA
    Clin Infect Dis 44:1543-8. 2007
    ..Strong consideration should be given to the use of alternative agents in the treatment of serious S. aureus infections...
  7. ncbi request reprint Antistaphylococcal vaccines and immunoglobulins: current status and future prospects
    Stan Deresinski
    Stanford University, Stanford, California, USA
    Drugs 66:1797-806. 2006
    ..This article reviews the biopharmaceutical progress made to date in this field and suggests approaches to further progress...
  8. ncbi request reprint Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data
    Stan Deresinski
    Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA, USA
    Clin Infect Dis 45:S177-83. 2007
    ..An appropriate response to this information often involves de-escalation of therapy or even its discontinuation...
  9. doi request reprint Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent
    Vijayalakshmi Nagappan
    Division of Infectious Diseases, St John Hospital and Medical Center, Detroit, Michigan, USA
    Clin Infect Dis 45:1610-7. 2007
    ..It may also have a role in the treatment of other filamentous fungal and some yeast infections, but assessment of its overall place in antifungal therapy awaits the availability of further clinical experience...